Skedsmokorset, Norway Clinical Trials

A listing of Skedsmokorset, Norway clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

macitentan 10 mg
left ventricular end-diastolic pressure
connective tissue disease
macitentan
ventricular septal defect
Akershus Universitetssykehus
 (5.1 away) Contact site
  • 37 views
  • 19 Jun, 2021
  • +263 other locations
A 2-part Trial to Learn More About How BAY1817080 Works How Safe it is and What the Right Dose is for Participants With Diabetic Neuropathic Pain

People suffering from diabetes often have high blood sugar levels. Over time this can affect many organs including the nerves in hands and feet and can cause a nerve pain called diabetic neuropathic pain (DNP). There are treatments for DNP but in many patients they do not reach a good …

Oslo universitetssykehus HF, Aker
 (9.3 away) Contact site
  • 0 views
  • 09 Jun, 2021
  • +64 other locations
Study of Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis

The purpose of the study is to assess preliminary efficacy, safety, and tolerability of LYS006 in patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.

hematochezia
endoscopy
Novartis Investigative Site
 (6.1 away) Contact site
  • 13 views
  • 17 Jun, 2021
  • +14 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

stage iv non-small cell lung cancer
stage iii non-small cell lung cancer
metastasis
carboplatin
lung carcinoma
Akershus Universitetssykehus HF ( Site 1106)
 (6.1 away) Contact site
  • 50 views
  • 17 Jun, 2021
  • +177 other locations
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line …

chemoradiotherapy
cancer chemotherapy
lung carcinoma
pembrolizumab
GSK Investigational Site
 (5.2 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +89 other locations
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

Akershus University Hospital
 (8.8 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +134 other locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

vegf
everolimus
growth factor
solid tumour
clear cell renal cell carcinoma
Akershus universitetssykehus ( Site 0851)
 (6.1 away) Contact site
  • 168 views
  • 20 Jun, 2021
  • +177 other locations
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International Multicentre Randomised-controlled Two-arm Assessor-blinded Trial

When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral anticoagulants (DOACs) are highly effective for secondary stroke prevention in these patients, but DOACs were never initiated <7 days after stroke onset in recent trials. …

ct scan
atrial fibrillation
edoxaban
apixaban
anticoagulants
Akershus University Hospital
 (8.8 away) Contact site
  • 370 views
  • 20 Jun, 2021
  • +114 other locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is …

systemic therapy
carcinoma
pembrolizumab
lenvatinib
clear cell renal cell carcinoma
Akershus universitetssykehus ( Site 2000)
 (6.1 away) Contact site
  • 0 views
  • 20 Jun, 2021
  • +42 other locations
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

conjugate vaccine
pneumococcal conjugate
Akershus University Hospital
 (8.8 away) Contact site
  • 0 views
  • 20 Jun, 2021
  • +71 other locations